FOLH1 and posterior cortical atrophy: With regards to bone-only oligometastatic PCa patients, previous studies [14] also documented PSMA-PET guided SBRT to be an effective treatment, with a 2-year PFS rate of 72.0%, a PSA decline in 75.7% of patients, and a 2-year local control rate per lesion of 95.4%.